| Home > Publications database > Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. |
| Journal Article | DKFZ-2025-00252 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
American Association for Cancer Research
Philadelphia, Pa.
This record in other databases:

Please use a persistent id in citations: doi:10.1158/2767-9764.CRC-24-0569
Abstract: Real-time molecular monitoring of TERT-rearranged high-risk neuroblastoma is an unmet clinical need. We tested liquid biopsy-based assays for patient-individualized TERT breakpoint sequences to monitor disease in pediatric patients. Our digital PCR approach provides high resolution of spatial and temporal disease quantification in individual patients and is applicable for clinical routine.
Keyword(s): Humans (MeSH) ; Neuroblastoma: genetics (MeSH) ; Neuroblastoma: pathology (MeSH) ; Telomerase: genetics (MeSH) ; Neoplasm, Residual: genetics (MeSH) ; Gene Rearrangement: genetics (MeSH) ; Circulating Tumor DNA: genetics (MeSH) ; Circulating Tumor DNA: blood (MeSH) ; Liquid Biopsy: methods (MeSH) ; Biomarkers, Tumor: genetics (MeSH) ; Biomarkers, Tumor: blood (MeSH) ; Child (MeSH) ; Child, Preschool (MeSH) ; Male (MeSH) ; Telomerase ; TERT protein, human ; Circulating Tumor DNA ; Biomarkers, Tumor
|
The record appears in these collections: |